



For Immediate Release

Symic to Present at the Boston Biotech CEO Conference

SAN FRANCISCO, May 24, 2016 – Symic, a clinical stage biotherapeutics company developing novel compounds that target and affect the extracellular matrix, today announced that Ken Horne, Chief Executive Officer, will present at the Boston Biotech Conferences Boston CEO Conference as part of the session “Next Generation Biotech CEOs and Board Members.”

Conference details:

Date: Tuesday, May 31, 2016

Time: 4:30-5:00 p.m. EDT

Location: Four Seasons Boston, 200 Boylston Street

About Symic

Symic is a clinical stage biotherapeutics company developing novel compounds that target and affect the extracellular matrix (ECM), the non-cellular component of tissue. The ECM plays a critical role in a wide variety of processes involved in acute and chronic indications. Symic’s proprietary compounds function like proteoglycans, which are naturally occurring macromolecules that play important structural and regulatory functions in the ECM. Symic currently has two clinical candidates, one in vascular injury and the other in osteoarthritis. In addition, Symic has several preclinical programs in oncology, fibrosis and CNS disorders.

For additional information please visit the company’s website at <http://www.symic.bio>, LinkedIn page www.linkedin.com/company/symic-bio/ or follow on Twitter at www.twitter.com/symicbio.

Media Contacts

David Schull or Lena Evans

Russo Partners, LLC

(212) 845-4271

(212) 845-4262

david.schull@russopartnersllc.com

lena.evans@russopartnersllc.com

###